⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17065917 | 0.97 | GSR (0.31) | — | |
| SCHEMBL15619050 | 0.83 | PKM (0.34) | — | |
| SCHEMBL16015626 | 0.80 | — | — | |
| SCHEMBL16330639 | 0.79 | CA3 (0.39) | — | |
| SCHEMBL5463082 | 0.78 | — | — | |
| SCHEMBL19505021 | 0.78 | — | — | |
| SCHEMBL15334952 | 0.75 | — | — | |
| SCHEMBL3431778 | 0.74 | — | — | |
| SCHEMBL15114199 | 0.74 | — | — | |
| SCHEMBL141561 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | claimed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | claimed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| EP-2162431-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | claimed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2025016273-A1 | ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USES OF ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION | 拜西欧斯（北京）生物技术有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20240376056-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240204253-A1 | COMPOUNDS FOR ENHANCING THE SOLID-ELECTROLYTE INTERPHASE (SEI) OF SILICON-BASED ANODE MATERIALS IN LITHIUM-ION BATTERIES, AND ELECTROLYTES, BATTERIES, AND METHODS RELATING THERETO | SILA NANOTECHNOLOGIES, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-1989011870-A1 | USE OF SPECIAL AMINES TO PREVENT NITROSAMINE FORMATION | MERCK PATENT GMBH (DE) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989011870-A1 | USE OF SPECIAL AMINES TO PREVENT NITROSAMINE FORMATION | MERCK PATENT GMBH (DE) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344564-A1 | Utilisation of special amines or hindering nitrosamine production | Eisenbrand, Gerhard, Prof. Dr. (DE) | 1989-12-06 | — | — | EP | disclosed |